Stake Super EOFY offer: Get $300 back for joining using the code EOFY2025. T&Cs apply.Start application

Ardelyx Inc

1 day chart

Kickstart your portfolio with a U.S. stock on us

Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.

Sign up and fund a new Wall St account and get a full U.S. share.

T&Cs apply
Claim now
Kickstart your portfolio with a U.S. stock on us

About ARDX

Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing first-in-class medicines. The Company has two commercial products approved in the United States: IBSRELA (tenapanor) and XPHOZAH (tenapanor). IBSRELA is a first-in-class NHE3 inhibitor approved by the United States FDA for the treatment of irritable bowel syndrome with constipation in adults. XPHOZAH is a first-in-class phosphate absorption inhibitor approved in the United States to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. It has agreements for the development and commercialization of tenapanor outside of the United States. Kyowa Kirin commercializes PHOZEVEL (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma.

Find out what a historical investment in Ardelyx Inc would be worth today using our ARDX stock calculator.

Market Capitalisation

$861.32M

Price-earnings ratio

-

Dividend yield

0.00%

Volume

6.01M

High today

$3.79

Low today

$3.58

Open price

$3.65

52-week high

$8.06

52-week low

$3.21

Ready to start your investing journey with Stake?

Open an account

ARDX FAQs

Buying ARDX shares in Australia can be done through an online investing platform, such as Stake. Follow the simple steps below to start investing in Ardelyx Inc in minutes.
  1. Sign up with some I.D. and zero paperwork
  2. Add funds to your account
  3. Make your first investment in ARDX

The ticker symbol for Ardelyx Inc is ARDX.

One share of ARDX is valued at $3.59 as of 15 June 2025.

As of 15 June 2025 Ardelyx Inc has a market cap of $861.32M.

The Ardelyx Inc 52-week high stock price is $8.06.

The Ardelyx Inc 52-week low stock price is $3.21.

Yes, the Stake investing platform allows you to buy ARDX shares and over 12,000 more stocks and ETFs across the ASX and Wall St.

This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.

Invest in ARDX
on Stake

Buy ARDX from US$3 brokerage

Invest in 9,500+ U.S. stocks and ETFs

Own a slice of ARDX from only US$10 with fractional shares

Get started
Stake app chart
Stock shown for demonstrative purposes only. US$3 brokerage up to US$30,000.
ARDX related stocks

Stake logo
Over 12,000 5-star reviews
App Store logoGoogle Play logo

Subscribe to our free newsletters

By subscribing, you agree to our Privacy Policy.

Stakeshop Pty Ltd, trading as Stake, ACN 610 105 505, is an authorised representative (Authorised Representative No. 1241398) of Stakeshop AFSL Pty Ltd (Australian Financial Services Licence no. 548196). Stake SMSF Pty Ltd ACN 648 283 532 (‘Stake Super’) is not licensed to provide financial product advice under the Corporations Act. This specifically applies to any financial products which are established if you instruct Stake Super to set up a self managed super fund (‘SMSF’). When you sign up to Stake Super, you are contracting with Stake SMSF Pty Ltd who will assist in the establishment of a SMSF under a ‘no advice model’. You will also be referred to Stakeshop Pty Ltd to enable your trading account and bank account to be set up in order to use the Stake Website and/or App. For more information about SMSFs, see our SMSF Risks page. The Stake Accumulate Fund (ARSN 680 653 374) is issued by K2 Asset Management Ltd (ABN 95 085 445 094 AFSL 244 393), a wholly owned subsidiary of K2 Asset Management Holdings Ltd (ABN 59 124 636 782). The information on our website or our mobile application is not intended to be an inducement, offer or solicitation to anyone in any jurisdiction in which Stake is not regulated or able to market its services. At Stake and Stake Super, we’re focused on giving you a better investing experience but we don’t take into account your personal objectives, circumstances or financial needs. Any advice given by Stake is of a general nature only. As investments carry risk, before making any investment decision, please consider if it’s right for you and seek appropriate taxation and legal advice. Please view our Financial Services GuideTerms & ConditionsPrivacy Policy and Disclaimers before deciding to invest on or use Stake or Stake Super. By using our website or service in any way, you agree to our Privacy Policy and Terms & Conditions. All financial products involve risk and you should ensure you understand the risks involved as certain financial products may not be suitable to everyone. Past performance of any product described on this website is not a reliable indication of future performance. Stake and Stake Super are registered trademarks in Australia.

Copyright © 2025 Stake. All rights reserved.